The Revised International Prognostic Index (R-IPI) for Diffuse Large B-cell Lymphoma predicts overall and progression free survival based on risk factors.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. The Diffuse …

2006年11月14日 · Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL), accounting for approximately 30% of all newly diagnosed cases …

2020年6月4日 · The revised IPI (R-IPI) was developed specifically for newly diagnosed patients with DLBCL to better risk-stratify those who were treated with R-CHOP. 2 The R-IPI used the …

2007年3月1日 · Redistribution of the IPI factors into a revised IPI (R-IPI) provides a more clinically useful prediction of outcome. The R-IPI identifies 3 distinct prognostic groups with a very good …

In this study we present the R/R-IPI, an international prognostic risk calculator for relapsed/refractory DLBCL. The model was developed and subsequently validated in large …

2023年10月13日 · We aimed to validate and compare different IPI-like variations to identify the model with the highest predictive accuracy for survival in newly diagnosed DLBCL patients. …

比较IPI、美国国家综合癌症网络IPI（NCCN-IPI）及年龄调整的IPI（aa-IPI）三种预后分层模型在弥漫大B细胞淋巴瘤（DLBCL）患者中的预后分层能力。 回顾性分析2003年1月至2012年12 …

我们评估了 1998 年至 2009 年间在 7 项多中心随机临床试验中使用一线 R-CHOP（或变体）治疗的 2124 名 DLBCL 患者，以确定哪种评分系统最能区分总生存期 (OS)。 中位年龄为 63 …

The original IPI, revised IPI (R-IPI) and NCCN-IPI are prognostic tools used to predict survival in patients with DLBCL. 1. Select score: R-IPI: Revised IPI score re-validated the original IPI …